LifeSci Capital analyst Patrick Dolezal maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR yesterday and set a price target of $72.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Patrick Dolezal has given his Buy rating due to a combination of factors including the promising outlook for Structure Therapeutics’ lead product, aleniglipron, in the obesity market. The company is on track to deliver top-line data from its ACCESS studies by the end of 2025, which could significantly boost investor confidence if the results align with expectations of a strong product profile. Additionally, the potential for a substantial upside in stock value exists if the clinical outcomes mirror those of competing products, with a projected 100% increase in value.
Moreover, Structure Therapeutics is advancing its pipeline with the initiation of a first-in-human study for its oral amylin agonist, ACCG-2671, and the development of ACCG-3535, which has shown competitive preclinical results. The company’s robust financial position, with approximately $800 million in cash, is expected to support its operations for over three years, providing a solid foundation for continued research and development. These factors collectively contribute to the positive outlook and the Buy rating assigned by Dolezal.
According to TipRanks, Dolezal is ranked #1345 out of 10072 analysts.